Threshold Pharma concludes recruitment in pancreatic cancer drug Phase 2 trial
TH-302 is a novel small molecule tumor selective hypoxia-activated prodrug (HAP) that specifically targets tumor hypoxia and is applicable to a broad range of solid tumors. Earlier, the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.